EnGeneIC and Singapore Institute of Advanced Medicine Form Partnership to Transform Cancer Treatment in Asia

EnGeneIC, a Sydney-based biopharmaceutical company, announced a strategic partnership with the Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). This collaboration is set to provide substantial funding to EnGeneIC, enabling the company to advance its clinical trials in Australia and the USA.

The partnership focuses on accelerating the development, manufacturing, and commercialization of EnGeneIC’s EnGeneIC Dream Vector (EDV™) technology for cancer treatment across Asia. Under the deal, SAM will obtain exclusive rights for the sales of EDV therapeutics in Asia, with net profits shared between the two companies, favoring EnGeneIC. Additionally, both entities will work together to develop EDV-based theranostics, a combination of therapeutic and diagnostic techniques aimed at enhancing cancer treatment outcomes. This innovative approach integrates imaging and treatment on a single platform, facilitating precise, personalized care and enabling early detection and targeted therapy.

The Crescendas Group, a diversified business entity in property, technology, and hospitality, is also a signatory to the partnership. The group, led by Singaporean businessman Lawrence Leow, has pledged funds for the necessary capital expenditure to advance clinical trials and secure FDA approval in the U.S. Crescendas operates in several countries, including Singapore, Malaysia, China, and the Maldives.

Dr. Jennifer MacDiarmid, Joint CEO of EnGeneIC, remarked that the partnership with SAM and SMI is a significant milestone as it expands their presence into Asia. She emphasized that EnGeneIC’s EDV technology has the potential to revolutionize cancer treatment. With the partners’ expertise and resources, the company is well-positioned to broaden its patient reach. Dr. Shih Kien Djeng, Chairman and CEO of SAM, expressed excitement about the collaboration, aligning it with SAM’s mission to advance medical innovation and improve patient outcomes. He highlighted the combined strengths aimed at delivering groundbreaking cancer treatments, offering new hope to patients in the region.

EnGeneIC is a clinical-stage biopharmaceutical company focused on its proprietary EDV® nanocell technology for oncology and infectious disease applications. The EDV™ nanocell forms the basis of a first-in-class antibody nanocell drug conjugate platform, delivering various therapeutic payloads with minimal toxicity. For cancer applications, this technology enables the delivery of potent chemotherapeutic agents, overcoming drug resistance, and killing tumor cells while simultaneously stimulating the patient’s immune system for a robust anti-tumor response. The company is currently in Phase IIa clinical trials in Australia and the USA, focusing on patients with challenging, low-survival cancers, including metastatic pancreatic cancer.

SAM is a healthcare service provider in Singapore specializing in advanced technology for early diagnosis and treatment of various diseases, including cancer, neurodegenerative, and cardiovascular diseases. Their services encompass Nuclear Medicine, Theranostics, Proton Therapy, and Radiation Therapy. SAM collaborates strategically with public and private institutions for research and clinical work.

In summary, EnGeneIC’s strategic partnerships with SAM and SMI mark a significant advancement in the development and commercialization of its cancer therapy technology in Asia. The collaboration, supported by Crescendas Group, aims to bring innovative cancer treatments to a broader patient population, combining resources and expertise to achieve regulatory approval and market success in the region.